ATE523591T1 - Verwendung eines ansatzes auf rnai-basis mit galectin-1 als ziel zur krebsbehandlung - Google Patents

Verwendung eines ansatzes auf rnai-basis mit galectin-1 als ziel zur krebsbehandlung

Info

Publication number
ATE523591T1
ATE523591T1 AT06707489T AT06707489T ATE523591T1 AT E523591 T1 ATE523591 T1 AT E523591T1 AT 06707489 T AT06707489 T AT 06707489T AT 06707489 T AT06707489 T AT 06707489T AT E523591 T1 ATE523591 T1 AT E523591T1
Authority
AT
Austria
Prior art keywords
cancer
hodgkin
lymphoma
melanoma
head
Prior art date
Application number
AT06707489T
Other languages
English (en)
Inventor
Isabelle Camby
Patrick Henriet
Florence Lefranc
Pierre Courtoy
Robert Kiss
Original Assignee
Univ Bruxelles
Univ Catholique Louvain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bruxelles, Univ Catholique Louvain filed Critical Univ Bruxelles
Application granted granted Critical
Publication of ATE523591T1 publication Critical patent/ATE523591T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT06707489T 2005-04-12 2006-03-09 Verwendung eines ansatzes auf rnai-basis mit galectin-1 als ziel zur krebsbehandlung ATE523591T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67033405P 2005-04-12 2005-04-12
PCT/EP2006/002170 WO2006108474A2 (en) 2005-04-12 2006-03-09 Use of a galectin-1-trageted rnai-based approach for the treatment of cancer

Publications (1)

Publication Number Publication Date
ATE523591T1 true ATE523591T1 (de) 2011-09-15

Family

ID=36933483

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06707489T ATE523591T1 (de) 2005-04-12 2006-03-09 Verwendung eines ansatzes auf rnai-basis mit galectin-1 als ziel zur krebsbehandlung

Country Status (9)

Country Link
US (1) US7964575B2 (de)
EP (1) EP1874930B1 (de)
JP (1) JP5242377B2 (de)
CN (1) CN101228274A (de)
AT (1) ATE523591T1 (de)
AU (1) AU2006233522A1 (de)
BR (1) BRPI0612334A2 (de)
CA (1) CA2604288C (de)
WO (1) WO2006108474A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8324367B2 (en) * 2006-11-03 2012-12-04 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
US9375440B2 (en) * 2006-11-03 2016-06-28 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
US9939428B2 (en) 2007-07-17 2018-04-10 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, and monitoring of immune disorders using galectin-1
US9206427B2 (en) 2007-07-17 2015-12-08 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the modulation of immune responses using galectin-1
CN104198712A (zh) * 2008-10-29 2014-12-10 Bg医药股份有限公司 半乳凝素-3免疫测定法
CN101984056B (zh) * 2009-07-10 2013-04-17 四川大学 人黑色素瘤细胞相关的长非编码rna的rna干扰靶点rna及用途
CN101619312B (zh) * 2009-07-10 2011-04-20 四川大学 人黑色素瘤细胞特异表达的长非编码rna序列及其用途
WO2011060272A2 (en) 2009-11-13 2011-05-19 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
US10314917B2 (en) 2013-03-15 2019-06-11 The Brigham And Women's Hospital, Inc. Targeted polymeric inflammation-resolving nanoparticles
AU2014293154A1 (en) 2013-07-24 2016-02-18 Dana-Farber Cancer Institute, Inc. Anti-galectin-1 monoclonal antibodies and fragments thereof
US11576976B2 (en) * 2015-01-21 2023-02-14 D. R. NANO Co., Ltd. Method of treating cancer by using siRNA nanocomplexes
RU2686313C2 (ru) * 2015-02-25 2019-04-25 Байонир Корпорейшн Фармацевтическая композиция для лечения рака, содержащая микроРНК в качестве активного ингредиента
GB201520600D0 (en) * 2015-11-23 2016-01-06 Univ Leuven Kath Treatment of central nervous tumours
CN107540738B (zh) * 2017-04-10 2020-04-24 清远职业技术学院 一种香港巨牡蛎半乳凝素ChGalectin及其制备方法和应用
US20210138080A1 (en) 2018-06-29 2021-05-13 Glykos Biomedical Oy Conjugates
US20230038373A1 (en) 2019-12-18 2023-02-09 Glykos Biomedical Oy Stabile conjugate
CN116785437B (zh) * 2023-06-16 2026-03-24 中国医学科学院肿瘤医院 KLF12或KLF12表达促进剂在制备用于抑制Galectin-1表达的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002081628A2 (en) * 2001-04-05 2002-10-17 Ribozyme Pharmaceuticals, Incorporated Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
EP1325116A2 (de) * 2000-10-04 2003-07-09 RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. Isoprenoid-abhängige ras-ankerproteine (idra)
US20020173478A1 (en) 2000-11-14 2002-11-21 The Trustees Of The University Of Pennsylvania Post-transcriptional gene silencing by RNAi in mammalian cells
WO2003070912A2 (en) * 2001-06-06 2003-08-28 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2002097114A2 (en) * 2001-05-29 2002-12-05 Sirna Therapeutics, Inc. Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv
US7148342B2 (en) * 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
WO2004012817A2 (en) 2002-07-31 2004-02-12 Kylix B.V. Use of genes identified to be involved in tumor development for the development of anti-cancer drugs
US20070178458A1 (en) * 2003-09-05 2007-08-02 O'brien Philippa Methods of diagnosis and prognosis of ovarian cancer II

Also Published As

Publication number Publication date
AU2006233522A1 (en) 2006-10-19
BRPI0612334A2 (pt) 2009-01-27
WO2006108474A3 (en) 2006-12-21
US20100120891A1 (en) 2010-05-13
WO2006108474A2 (en) 2006-10-19
JP2008535504A (ja) 2008-09-04
CN101228274A (zh) 2008-07-23
JP5242377B2 (ja) 2013-07-24
CA2604288C (en) 2021-07-06
EP1874930A2 (de) 2008-01-09
CA2604288A1 (en) 2006-10-19
US7964575B2 (en) 2011-06-21
EP1874930B1 (de) 2011-09-07

Similar Documents

Publication Publication Date Title
ATE523591T1 (de) Verwendung eines ansatzes auf rnai-basis mit galectin-1 als ziel zur krebsbehandlung
Gao et al. LncRNA PCAT1 activates SOX2 and suppresses radioimmune responses via regulating cGAS/STING signalling in non‐small cell lung cancer
WO2005100998A3 (de) Membrane markers for use in cancer diagnosis and therapie
WO2008020596A3 (en) Treating or preventing cancers over-expressing reg4 or kiaa0101
NZ626867A (en) Compositions and methods for the treatment of infections and tumors
WO2016106400A3 (en) Rna interference agents for gst-pi gene modulation
WO1999022773A3 (en) Sequences for targeting metastatic cells
ATE420160T1 (de) Modifizierte rekombinante vacciniaviren, verwendungen davon
NZ591137A (en) Methods and systems for predicting response of cells to a therapeutic agent
BRPI0808940A8 (pt) anticorpo humano ou fragmento de ligação do mesmo, antígeno, polinucleotídeo, vetor, célula hospedeira, método para preparar um anticorpo ou um fragmento de ligação ou cadeia(s) de imunoglobulina do mesmo, anticorpo, cadeia de imunoglobulina ou um fragmento de ligação do mesmo, composição, usos do anticorpo ou fragmento de ligação, de um antígeno, de um polinucleotídeo, de um vetor, ou de uma célula, e de uma molécula de ligação a antígeno tumoral, método para clonagem molecular de um anticorpo, e, kit para o diagnóstico de um tumor
WO2007144985A1 (ja) Ｒｐｎ２遺伝子発現抑制剤の用途
UA99602C2 (ru) Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток
MX2009009816A (es) Anticuerpos monoclonales para el tratamiento del cancer.
WO2005116259A3 (en) Use of gene expression profiling to predict survival in cancer patient
WO2021092464A3 (en) Chemically modified oligonucleotides targeting bromodomain containing protein 4 (brd4) for immunotherapy
MX2023007788A (es) Inhibidores de la atp sintasa, usos cosmeticos y terapeuticos.
CN104610435B (zh) 一种能靶向抑制erk信号通路的抗肿瘤多肽及其应用
WO2004074437A3 (en) Compositions and methods for cancer immunotherapy
GB0418388D0 (en) Cell therapy
ATE514718T1 (de) Peptabody für krebsbehandlung
Zou et al. RACK1 silencing induces cell apoptosis and inhibits cell proliferation in hepatocellular carcinoma MHCC97-H cells
WO2013066485A3 (en) Compositions and methods for treatment of metastatic cancer
WO2005090572A3 (en) Compositions and methods for treating pancreatic cancer
Kaszuba-Zwoińska et al. Changes in cell death of peripheral blood lymphocytes isolated from children with acute lymphoblastic leukemia upon stimulation with 7 Hz, 30 mT pulsed electromagnetic field.
CN106244592B (zh) 一种长非编码rna及其在诊断/治疗非小细胞肺癌中的应用

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties